PT  - JOURNAL ARTICLE
AU  - Natasha Yumi Matsunaga
AU  - Tais Nitsch Mazzola
AU  - Marina Simões Oliveira
AU  - Livea Gianfrancesco
AU  - Bruna Cunha Zaidan
AU  - Icléia Siqueira Barreto
AU  - André Moreno Morcillo
AU  - Mariana Dalbo Contrera Toro
AU  - Maria Cristina Ribeiro Dos Santos Simões
AU  - Maria Angela Gonçalves De Oliveira Ribeiro
AU  - Jose Dirceu Ribeiro
AU  - Adyléia Aparecida Dalbo Contrera Toro
TI  - Clinical characteristics, lung function, quality of life, exercise capacity and inflammatory biomarkers in induced sputum and serum in children and adolescents with uncontrolled severe asthma
AID  - 10.1183/13993003.congress-2019.PA954
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA954
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA954.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA954.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Background: Severe uncontrolled asthma can result in a higher risk of severe exacerbations frequency, an increased risk for adverse reactions to medications, chronic morbidity and death.Aims: to assess and follow-up children and adolescents with uncontrolled severe asthma.Methods: We assessed all children and adolescents with asthma from 7-17 years old from Pediatric Pulmonology Outpatient Clinic of Unicamp and selected those who were classified as “uncontrolled severe asthma”. These patients were assessed and followed up for six months, and answered a questionnaire with clinical information, Asthma Control Test and Pediatric Asthma Quality of Life Questionnaire, and performed a skin prick test, spirometry, six-minute walk test, induced sputum and blood collection to assessment total immunoglobulin E and eosinophil count. Cytokine dosage for IL-17, IL-13, IL12/IL23p40, IL-10, IL-6, IL-4, IL-2, IFN-γ and TNF were analyzed in sputum supernatant and serum sample by Cytometric Bead Array (CBA, BD Biosciences, USA).Results: Out of 261 patients assessed, 33 subjects were included in this study. When comparing visit 1 and visit 2, we observed differences in satisfactory adherence among patients, achieving asthma control in 50% of them, decreased exacerbation occurrence (p<0.001), improved quality of life scores (p<0.05) and changed in serum IL-13 levels (p=0.043).Conclusion: Patients with uncontrolled severe asthma showed improvement of asthma control, quality of life and number of exacerbations. Regarding inflammatory biomarkers, IL-13 presented difference between visit 1 and visit 2.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA954.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).